东亚药业: 东亚药业关于回购注销部分激励对象已获授但尚未解除限售的限制性股票的公告

Core Viewpoint - The company announced the repurchase and cancellation of 14,000 restricted stocks due to one incentive object resigning, with a repurchase price of 9.47 yuan per share [1][6][10]. Summary by Sections Announcement Details - The company’s board approved the repurchase of restricted stocks at a meeting held on June 30, 2025, following the resignation of one incentive object [1][2]. - The total number of restricted stocks to be repurchased is 14,000 shares, which represents 0.01% of the total share capital of 114,739,776 shares as of June 29, 2025 [6][7]. Repurchase Price and Funding - The repurchase price for the restricted stocks is set at 9.47 yuan per share, totaling 132,580 yuan, which will be funded entirely from the company’s own funds [6][7]. Impact on Share Capital Structure - After the repurchase and cancellation, the company’s total share capital will decrease from 114,739,776 shares to 114,725,776 shares [7][9]. - The number of restricted shares will decrease from 2,156,103 to 2,142,103 shares, while the number of unrestricted shares remains unchanged at 112,583,673 [8]. Compliance and Approval - The repurchase has been authorized by the company’s third extraordinary general meeting in 2024, and no further shareholder approval is required [6][9]. - The supervisory board has confirmed that the repurchase complies with relevant regulations and will not adversely affect the company’s financial status or operational results [9][10].